Tweets by @pharma_BI and @AVIVA1950 for #PMConf at The 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115
Curator: Aviva Lev-Ari, PhD, RN
@pharma_BI
@AVIVA1950
All TWEETS from LPBI’s Twitter.com handles at #PMConf
-
-
-
Aviva Lev-Ari Retweeted Gary An
nice comment
Aviva Lev-Ari added,
-
#PMConf@pharma_BI@AVIVA1950 LIVE Day Two – 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, … https://pharmaceuticalintelligence.com/2017/11/16/live-day-two-13th-annual-personalized-medicine-from-concept-to-the-clinic-november-14-16-2017-joseph-b-martin-conference-center-harvard-medical-school-77-avenue-louis-pasteur-bos/ … via@Pharma_BI -
#PMConf@pharma_BI@AVIVA1950 Narrative plan unsupported by facts -
#PMConf@pharma_BI@AVIVA1950 Robert C. Green, M.D., M.P.H., Director, Genomes2People Research Program, Professor of Medicine (Genetics), Brigham and Women’s Hospital, Broad Institute and Harvard Medical School pharmacogenomics can harm if odds are so low adherence will be lower -
#PMConf@pharma_BI@AVIVA1950 Michael Snyder, Ph.D., Stanford W. Ascherman Professor, Chair, Department of Genetics, Director, Center of GenomiPersonalized Medicine, Stanford University School of Medicine Personal sequencing for multiple etiologies rich people are sequenced -
#PMConf@pharma_BI@AVIVA1950 Tom Miller, M.S., Founder, Managing Partner, GreyBird Ventures LLC duty to call up therapies that will not work, balance addressed by PM – diagnostics in PM clinical utility from patient selection for the therapy the patient will respond to -
#PMConf@pharma_BI@AVIVA1950 Sandro Galea, M.D., School of Public Health, Boston University US expense on Health care the highest in the World comes on the expense of housings, mental health, education – curative vs preventive care MDs are insentiviced to keep patients sick -
#PMConf@pharma_BI@AVIVA1950 Robert C. Green, M.D., Broad Institute and HMS Platinum vs gold standard 59 genes will identify 80,000 will get the disease and 47,000 will never get the disease, is the technology the reason for investment vs Family history? -
#PMConf@pharma_BI@AVIVA1950 Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation Genome sequencing found his Pi3K Pathway – PIK3CA p.E54 – Anti Inhibitor for Pi3K = Precision Medicine -
#PMConf@pharma_BI@AVIVA1950 Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA 21st Century – metastatic solid tumors – 900 patients: accommodated plan Lab developed Tests: new approach Efficiency, transparency -
#PMConf@pharma_BI@AVIVA1950 innovation INFORMS at NIH Center of Excellence – data collection and analysis of multiple data types Biometric sensors collecting data on cancer patients collaboration with Academia, single arm vs randomized decentralized devices are collecting data -
#PMConf@pharma_BI@AVIVA1950 FDA considers N of One, small samples, EGFR drug was approved in 2 1/2 years since Phase 1 of NDA New trial designs: reduce bias and alternative end points narrow criteria for participation, more personalized and more patient-centered innovation -
#PMConf@pharma_BI@AVIVA1950 Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA Advances of technology of biomarkers, disease indication Accelerated approval by FDA a collaborative of speeding the process companion diagnosis assays -
#PMConf@pharma_BI@AVIVA1950 Unmet need, commitment is there, innovation and connectivity drive access, collaboration not competition – helps Precision medicine in emerging nations. Access to PM anywhere in the world suggested Kristin Pothier, MS, Global Head, Life Sciences EY -
#PMConf@pharma_BI@AVIVA1950 Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Board Chairman, PMC Laxo – A molecular target to be found by diagnostics TEST — as a basis to develop a drug Pricing and value – dimensions of Value to society How PM is done today? -
#PMConf@pharma_BI@AVIVA1950 Marc S. Williams, MD Geisinger Clinical Genomics vs Physician specialist (i.e.,hypercholestoralemia), both in same place – paper and EMR Outcomes – tracking patients over decades – systems in place to capture the data Virtual Cycle Clinical data -
#PMConf@pharma_BI@AVIVA1950 Timothy Cannon, M.D., Inova Molecular Tumor Board, 5 hospital in VA, Precision Genomics Cancer Therapy Poor understanding of molecular results by MDs, Refractory Patients no Forum to discuss other options 220 patients presented beyond InovaOncologi -
#PMConf@pharma_BI@AVIVA1950 Scott A. Beck, Mayo Clinic, MN, AZ PM, Genomics sequencing, BioEthics, IT, Translational Perspective in Epi-genomics, Discovery to Translation Applicattions Pharmacy- Formulary – EMR – Champions from Disease areas to practice environment Testing -
#PMConf@pharma_BI@AVIVA1950 payment dominates delivery of care, future PM from Genomics cost to patients Transform acceptability of PM suggested Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO -
#PMConf@pharma_BI@AVIVA1950 Genomics based PM to be turned into Wellness Strategy – the path not yet knows said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN -
#PMConf@pharma_BI@AVIVA1950 Millianlian Diabetics NOT on Medicare, Analytics: iPhone telling patient dishes to order since SYSTEM KNOWS BLOOD SUGER 24×7 – target care by Analytics Genomics paid by NIH PM Analytics is built at Vanderbilt University MC, Jeffrey R. Balser, CEO -
#PMConf@pharma_BI@AVIVA1950 LIVE Day One – 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, … https://pharmaceuticalintelligence.com/2017/11/15/live-day-one-13th-annual-personalized-medicine-from-concept-to-the-clinic-november-14-16-2017-joseph-b-martin-conference-center-harvard-medical-school-77-avenue-louis-pasteur-bos/ … via@Pharma_BI -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Survival of patient with mutation and targeted drug LIVE LONGER David B. Roth, M.D., Ph.D., Simon Flexner Professor Chair, Pathology and Laboratory Medicine, Perelman School of Medicine at University of Pennsylvania -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Lotte Steuten, Ph.D., School of Pharmacy at University of Washington, Seattle aggregate big data , models as evidence, has value to clinical, the model under development NGS Profile of Patient vs current standard of care. -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 David B. Roth, M.D., Ph.D., UPenn Director, Penn Center for Precision Medicine 5000 patients underwent genome sequencing Interpretation is the issue that is hard Health IT are still in silos: Pharmacy data, financial data, EMR -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Michael Pellini, M.D., M.B.A., Chairman, Board of Directors, Foundation Medicine; Board Member, Personalized Medicine Coalition, we know there is value in PM we need to work together on the challenges — to prove the value in PM -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Andrea Stern Ferris, M.B.A., President, Chairman of the Board, LUNGevity Foundation – PATIENT to be included in the conversation patient after successful treatment have hope work pay taxes pay to health plans continue family life -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Molecular Era, NEJM, 2017, 377, 1813-1823, BRAF in Melanoma – 80% do not need additional therapy vs 20% benefitted in the Non-Molecular Era, data by Dane J. Dickson, CureOne (formerly MED-C); Oregon Health and Science University -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 CURES – CAR-T are they cures??? A teen-ager’s Value-based Price: $475,000 x years lived suggests Steven D. Pearson, M.D., M.Sc., Founder, President, Institute for Clinical and Economic Review (ICER) -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Of 134 drugs in development – 42 have the potential to become Personalized medicine therapies, said Stephen J. Ubl, President, CEO, PhRMA -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Transplantation vs enhancement – resistance to senescence and pathogens to be achieved by gene editing suggests George M. Church, Ph.D., Professor of Genetics -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Regulatory oversight on engineering embrios is coming, metric of success in recruitment of patients said Arthur L. Caplan, Ph.D., Drs. William F. and Virginia Connolly Mitty Chair, Director, Division of Medical Ethics, New York Univ -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 CRISPR does not handle all mutation many require a different editing tool said George M. Church, Ph.D., Professor of Genetics, Health Sciences and Technology, Harvard-MIT Division of Health Sciences and Technology -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 understand well enough the gentic application where CRISPR will assist medicine: Retinal degeneration, two aspects one worked in Japan said Katrine Bosley, CEO, Editas Medicine -
Aviva Lev-Ari Retweeted Aviva Lev-Ari
Amazing Power in hands of informed patients
Aviva Lev-Ari added,
-
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Patients input and sophistication increased – IRB is not aware of the engagement of Patients and their challenging feedback say Deborah Schrag, M.D., M.P.H, Dana Farber -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Physicians needs interfaces, dashboard information delivered to MDs, data sits unused, new tools are needed for the data display by relevance to the MDs – clinicians needs decision support in their office -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Standards: Toxicity criteria – library of 882 symptoms, Patient reported outcomes by Patients, Resist criteria applied to imaging data criteria for brain tumors said Deborah Schrag, M.D., M.P.H., Chief Medical Oncology, Dana-Farber -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 drafting document on Verify data integrity in clinical trials, detect discrepancies compromise the integrity of the data – audits by FDA said Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 pre-existing autoimmune disease – not indicated for them Immunotherapy even though patients wish to try said Deborah Schrag, M.D., M.P.H., Chief, Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Drug approved for one indication, provide new data for supplemental indications said Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Eric G. Klein, Pharm.D, Eli Lilly Aggregate burden of disease, existence of co-morbidities Genomics: WHY is explained – precise tools data vs intelligence – interoperability Past clinical trial, replicate studies retrospective data -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 linkages vs computational techniques we do not have consistent data, data structured Vital sign or WBC count – we have data standardization is evolving said Deborah Schrag, M.D., M.P.H., Chief, Dana-Farber Cancer Institute -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 use data sets prospective vs retrospective studies asked Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Flatiron Health; Board Member, Personalized Medicine Coalition -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Clinical sense vs research context, FDA is more comfortable with other than oncology products beyond drugs, namely diagnostics, diagnostics company seeking partnership with many drug areas Thermo FIscher and Novartis partnership -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 Cost of CT Scan vs an NGS Test – Genomic testing is much cheaper yet volume is still low said Jacob S. Van Naarden, Chief Business Officer, Loxo Oncology -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 NGS – time results come back what the mutation mean? NOW results come in few days, data analysis assist the said Joydeep Goswami, Ph.D., M.B.A., M.S., President, Clinical Next-Generation Sequencing, Oncology, Thermo Fisher Scientifi -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 3D BioPrinting of Drugs and the innovation storm of agents — are both benefits, value based pricing, elasticities, is that price sufficient to support R&D, dynamic environment said Joshua Ofman, SVP, Global Value, Access, Amgen -
#PMConf@AVIVA1950@Pharma_BI Awardee of Leadership in PM, Illumina, HC system not yet ready for Precision Medicine
-
#PMConf@Pharma_BI@AVIVA1950 Amgen and Harvard Pilgrims interpretation of Values related to partnerships: Novartis
-
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 at Illimina – Consumer Advocacy added to Technology breakthroughs in genome sequencing said Jay T. Flatley, M.S., Executive Chairman, Illumina -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 National Genomic Service – Sequencing becoming STANDARD of Care, phynotypes, $10 million to be spent NIH said Jay T. Flatley, M.S., Executive Chairman, Illumina -
#PMConf@PartnersPersMed@pharma_BI@AVIVA1950 13th Annual Leadership in Personalized Medicine Award AWARDEE | Jay T. Flatley, M.S., Executive Chairman, Illumina -
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply